{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:23:53Z","timestamp":1793197433719,"version":"4.5.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T00:00:00Z","timestamp":1661212800000},"content-version":"vor","delay-in-days":50,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Expanding the use of temocillin could be an important weapon in the fight against antimicrobial resistance. However, EUCAST defined clinical breakpoints for a limited number of species and only for urinary tract infections (UTI), including urosepsis but excluding severe sepsis and septic shock. Moreover, a dosage of 2\u2005g q8h is advised in most cases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Evaluation of temocillin use for the treatment of bacteraemia, correlating clinical and microbiological outcomes with infection site, infection severity, temocillin dosage, Enterobacterales species and MIC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and methods<\/jats:title>\n                  <jats:p>All adult patients with blood cultures positive for temocillin-susceptible Enterobacterales and treated with temocillin for \u226572\u2005h from June 2018 until June 2021 were considered for inclusion. The primary outcome was clinical success, defined as resolution of infection signs, no relapse of the same infection and no antibiotic switch due to insufficient clinical improvement. The secondary outcome was microbiological success.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 182 episodes were included [140 UTI versus 42 non-UTI, 171 Escherichia coli, Klebsiella species (except Klebsiella aerogenes) and Proteus mirabilis (EKPs) versus 11 non-EKPs]. Clinical and microbiological failure were low (8% and 3%, respectively). No difference in outcome was observed for dosages of 2\u2005g q12h versus 2\u2005g q8h, either for EKP versus non-EKP isolates or MIC values \u22648 versus 16\u2005mg\/L. Considering only bacteraemia episodes of UTI origin, using the 16\u2005mg\/L breakpoint, there was no difference in success rate between regimens of 2\u2005g q12h and 2\u2005g q8h.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Temocillin 2\u2005g q12h can be successfully used for the treatment of systemic UTI. Prospective studies are needed to assess outcomes and evaluate non-inferiority compared with other broad-spectrum antibiotics in non-UTI infections, including bacteraemia.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jacamr\/dlac086","type":"journal-article","created":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T12:38:07Z","timestamp":1661258287000},"source":"Crossref","is-referenced-by-count":16,"title":["Clinical and microbiological evaluation of temocillin for bloodstream infections with Enterobacterales: a Belgian single-centre retrospective study"],"prefix":"10.1093","volume":"4","author":[{"given":"Julie","family":"Oosterbos","sequence":"first","affiliation":[{"name":"Ziekenhuis Oost-Limburg hospital , Genk , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaike","family":"Schalkwijk","sequence":"additional","affiliation":[{"name":"Ziekenhuis Oost-Limburg hospital , Genk , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Thiessen","sequence":"additional","affiliation":[{"name":"Ziekenhuis Oost-Limburg hospital , Genk , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Els","family":"Oris","sequence":"additional","affiliation":[{"name":"Ziekenhuis Oost-Limburg hospital , Genk , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Coppens","sequence":"additional","affiliation":[{"name":"Ziekenhuis Oost-Limburg hospital , Genk , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrien","family":"Lagrou","sequence":"additional","affiliation":[{"name":"Katholieke Universiteit Leuven , Leuven , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Steensels","sequence":"additional","affiliation":[{"name":"Ziekenhuis Oost-Limburg hospital , Genk , Belgium"},{"name":"Universit\u00e9 Libre de Bruxelles , Brussels , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,8,23]]},"reference":[{"key":"2022082312375785100_dlac086-B1","article-title":"Comparative in vitro activity of piperacillin-tazobactam and temocillin against third-generation cephalosporin-resistant, carbapenem-susceptible Escherichia coli and Klebsiella pneumoniae","volume":"9","author":"Kresken","year":"2021","journal-title":"GMS Infect Dis"},{"key":"2022082312375785100_dlac086-B2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.medmal.2018.10.007","article-title":"In vitro activity of temocillin against extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae strains isolated from urinary tract infections in France","volume":"49","author":"Duployez","year":"2019","journal-title":"Med Mal Infect"},{"key":"2022082312375785100_dlac086-B3","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1128\/AAC.22.3.453","article-title":"Antibacterial activity and \u03b2-lactamase stability of temocillin","volume":"22","author":"Jules","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082312375785100_dlac086-B4","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.cmi.2015.05.022","article-title":"Contemporary resistance trends and mechanisms for the old antibiotics colistin, temocillin, fosfomycin, mecillinam and nitrofurantoin","volume":"21","author":"Giske","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"2022082312375785100_dlac086-B5","volume-title":"Carboxypenicillines-Temocilline-Negaban","author":"BCFI","year":"2022"},{"key":"2022082312375785100_dlac086-B6","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1093\/jac\/dkaa356","article-title":"Temocillin dosage adjustment in a preterm infant with severe renal disease: a case report","volume":"75","author":"Dumangin","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2022082312375785100_dlac086-B7","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02052-21","article-title":"Modelled target attainment after temocillin treatment in severe pneumonia: systemic and epithelial lining fluid pharmacokinetics of continuous versus intermittent infusions","volume":"66","author":"Layios","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082312375785100_dlac086-B8","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/BF02148656","article-title":"Interpretive criteria for temocillin disk diffusion susceptibility testing","volume":"4","author":"Fuchs","year":"1985","journal-title":"Eur J Clin Microbiol"},{"key":"2022082312375785100_dlac086-B9","article-title":"Methods for Antimicrobial Susceptibility Testing","author":"BSAC"},{"key":"2022082312375785100_dlac086-B10","article-title":"Comit\u00e9 de l\u2019Antibiogramme de la Soci\u00e9t\u00e9 Fran\u00e7aise de Microbiologie","author":"CA-FSM"},{"key":"2022082312375785100_dlac086-B11","article-title":"EUCAST General Consultation on Breakpoints for Temocillin, Consultation Period 11 October 2019\u201330 November 2019","author":"EUCAST"},{"key":"2022082312375785100_dlac086-B12","doi-asserted-by":"crossref","first-page":"R126","DOI":"10.1186\/cc9091","article-title":"Insufficient \u03b2-lactam concentrations in the early phase of severe sepsis and septic shock","volume":"14","author":"Taccone","year":"2010","journal-title":"Crit Care"},{"key":"2022082312375785100_dlac086-B13","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1093\/jac\/dkab081","article-title":"Comment on: Efficacy of temocillin against MDR Enterobacterales: a retrospective cohort study","volume":"76","author":"Giske","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2022082312375785100_dlac086-B14","article-title":"Penicillines: Temocilline. BVIKM","author":"Belgische Vereniging voor Infectiologie en Klinische Microbiologie"},{"key":"2022082312375785100_dlac086-B15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0732-8893(84)90023-3","article-title":"Temocillin: in vitro activity against 734 selected clinical isolates, including \u03b2-lactamase-producing strains","volume":"2","author":"Fuchs","year":"1984","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2022082312375785100_dlac086-B16","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1001\/jama.2016.0289","article-title":"Developing a new definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Shankar-Hari","year":"2016","journal-title":"JAMA"},{"key":"2022082312375785100_dlac086-B17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0002-9343(84)90770-8","article-title":"Clinical importance of \u201cbreakthrough\u201d bacteremia","volume":"76","author":"Weinstein","year":"1984","journal-title":"Am J Med"},{"key":"2022082312375785100_dlac086-B18","article-title":"Nationale Surveillance van Bloedstroominfecties in Belgische Ziekenhuizen","author":"Sciensano"},{"key":"2022082312375785100_dlac086-B19","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1093\/jac\/dkr317","article-title":"Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and\/or derepressed AmpC \u03b2-lactamase-producing Enterobacteriaceae","volume":"66","author":"Balakrishnan","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2022082312375785100_dlac086-B20","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/jac\/dkaa486","article-title":"Efficacy of temocillin against MDR Enterobacterales: a retrospective cohort study","volume":"76","author":"Alexandre","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2022082312375785100_dlac086-B21","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlab005","article-title":"Clinical outcomes of temocillin use for invasive Enterobacterales infections: a single-centre retrospective analysis","volume":"3","author":"Heard","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"2022082312375785100_dlac086-B22","article-title":"EUCAST General Consultation \u2013 Responses to Comments Received","author":"EUCAST"},{"key":"2022082312375785100_dlac086-B23","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.ijantimicag.2019.07.003","article-title":"Clinical cure rate and cost-effectiveness of carbapenem-sparing \u03b2-lactams vs. meropenem for Gram-negative infections: a systematic review, meta-analysis, and cost-effectiveness analysis","volume":"54","author":"Nguyen","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2022082312375785100_dlac086-B24","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s10096-021-04158-w","article-title":"Temocillin as an alternative treatment for acute bacterial cholangitis: a retrospective microbiology susceptibility-based study of 140 episodes","volume":"40","author":"Chawki","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2022082312375785100_dlac086-B25","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1007\/s10096-015-2406-x","article-title":"Amoxicillin plus temocillin as an alternative empiric therapy for the treatment of severe hospital-acquired pneumonia: results from a retrospective audit","volume":"34","author":"Habayeb","year":"2015","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2022082312375785100_dlac086-B26","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/jac\/dku465","article-title":"Temocillin (6\u2005g daily) in critically ill patients: continuous infusion versus three times daily administration","volume":"70","author":"Laterre","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2022082312375785100_dlac086-B27","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s40262-017-0584-7","article-title":"Pharmacokinetics and pharmacodynamics of temocillin","volume":"57","author":"Alexandre","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"2022082312375785100_dlac086-B28","doi-asserted-by":"crossref","first-page":"dlab192","DOI":"10.1093\/jacamr\/dlab192","article-title":"Activity of temocillin against third-generation cephalosporin-resistant Escherichia coli and Klebsiella pneumoniae bloodstream isolates from a clinical trial","volume":"4","author":"Stewart","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"2022082312375785100_dlac086-B29","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1128\/AAC.22.4.535","article-title":"In vitro activity of temocillin (BRL 17421), a novel \u03b2-lactam antibiotic","volume":"22","author":"Van Landuyt","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082312375785100_dlac086-B30","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/jac\/dkm467","article-title":"Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection","volume":"61","author":"De Jongh","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"2022082312375785100_dlac086-B31","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.diagmicrobio.2012.11.009","article-title":"Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes","volume":"75","author":"van Duin","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2022082312375785100_dlac086-B32","doi-asserted-by":"crossref","first-page":"e0248177","DOI":"10.1371\/journal.pone.0248177","article-title":"Impact of ceftriaxone and temocillin on fecal abundance of extended-spectrum \u03b2-lactamase producing Escherichia coli in a mouse model","volume":"16","author":"Chenouard","year":"2021","journal-title":"PLoS One"},{"key":"2022082312375785100_dlac086-B33","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.ijantimicag.2018.08.026","article-title":"Carbapenems and alternative \u03b2-lactams for the treatment of infections due to extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae: What impact on intestinal colonisation resistance?","volume":"52","author":"Woerther","year":"2018","journal-title":"Int J Antimicrob Agents"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/4\/4\/dlac086\/45500464\/dlac086.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/4\/4\/dlac086\/45500464\/dlac086.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T12:38:29Z","timestamp":1661258309000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlac086\/6673847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,4]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlac086","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8,1]]},"published":{"date-parts":[[2022,7,4]]},"article-number":"dlac086"}}